The United States of America, as Represented by the Secretary, Department of Health and Human Services

Other

University System of Maryland

The University of Tokyo

Icahn School of Medicine at Mount Sinai

New England Biolabs, Inc.

Patricia Dranchak

James Inglese

Wei Ping Zheng

Juan Jose Marugan

Hiroaki Suga

Noel Terrence Southall

Mark A Hoon

Samarjit Patnaik

Clotilde K Carlow

Zhiru Li

Yiannis A Ioannou

Marc Ferrer-Alegre

Joseph G Hacia

Hao Yu

Hans Juergen Solinski

Nancy E Braverman

Ryan MacArthur

Mercedes Taylor

Raul Rolando Calvo

Seameen Dehdasthi

Fannie Chen

Songon An

Danielle L Schmitt

A cell-based quantitative high-throughput screening assay to monitor the formation of PFK1-mEGFP clusters by the action of small molecules to identify small molecules that promote intracellular PFK1 clustering in a cell cycle-dependent manner and may be used to treat cancer.

Method of identifying a compound which affects the multienzyme metabolic assembly of glucose metabolism and its association with cell cycle progression in cancer cells

Pharmaceutical compositions comprising a molecular inhibitor of Npr1 are disclosed. Also disclosed are methods of treating, reducing, or preventing acute and/or chronic pruritus in a mammal comprising administering a pharmaceutical composition comprising a molecular inhibitor of Npr1.

Compositions and methods for the inhibition of pruritus

Provided herein are methods of treating Zellweger spectrum disorder (ZSD) in a subject in need thereof or improving peroxisome assembly in a cell in need thereof comprising administering to the subject a therapeutically effective amount of Compounds of Formula I or II.

Compositions and methods for the treatment of Zellweger spectrum disorder

Disclosed herein are isolated peptides inhibit activity of a cofactor-independent phosphoglycerate mutase. In some examples, the isolated peptide is 6-20 amino acids long and includes the amino acid sequence of any one of SEQ ID NOs: 1-22 or 54, an analog or derivative thereof, or a pharmaceutically acceptable salt or ester thereof. In some examples, the peptide is a cyclic peptide with an N-terminal ring of 6-15 amino acids (for example, 6-10 amino acids) and a C-terminal linear portion of 1-9 amino acids (for example, 3-8 amino acids. Also disclosed h are methods of treating or inhibiting an infection in a subject, including administering to the subject an effective amount of a composition including one of more of the disclosed peptides, or analogs or derivative thereof, or pharmaceutically acceptable salts or esters thereof.

Peptide inhibitors of phosphoglycerate mutase and methods of use

Methods and compositions for treating lysosomal storage disorders are disclosed. The methods involve administering a genus of benzenesulfonamides, particularly N-[3-(aminosulfonyl)phenyl]-benzamides and heteroarylamides. A genus of suitable compounds is shown in formula 1: 

Benzenesulfonamide upregulators of NPC1 for Neimann-Pick disease and other lysosomal storage disorders

Growing community of inventors

Gaithersburg, MD, United States of America

Patricia Dranchak